Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib after alectinib or ceritinib in ALK-positive advanced non-small cell lung cancer
2018-000635-27Phase 2Completed
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brigatinib in non-small cell lung cancer (NSCLC) and ALK-positive non-small cell lung cancer, sponsored by ARIAD Pharmaceuticals, Inc. Primary endpoint: Confirmed objective response rate. Started Aug 2018; status: completed.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on 2018-000635-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000635-27.